This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

This study has been completed.
Information provided by (Responsible Party):
Ocular Therapeutix, Inc. Identifier:
First received: August 14, 2012
Last updated: March 15, 2017
Last verified: March 2017
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.

Condition Intervention Phase
Ocular Inflammation and Pain Drug: OTX-DP (Dexamethasone punctum plug) Drug: Placebo Vehicle Punctum Plug Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase II Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery

Resource links provided by NLM:

Further study details as provided by Ocular Therapeutix, Inc.:

Primary Outcome Measures:
  • Absence of Cells in Anterior Chamber of Study Eye [ Time Frame: Day 8 ]
  • Absence of Pain in the Study Eye [ Time Frame: Day 8 ]

Other Outcome Measures:
  • Adverse Events [ Time Frame: Duration of each individual subject's participation in the study ]
    Measure of adverse events over the duration of each subject's participation in the study.

Enrollment: 60
Actual Study Start Date: October 2012
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Dexamethasone Punctum Plug
Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
Drug: OTX-DP (Dexamethasone punctum plug)
Sustained and tapered release of dexamethasone from hydrogel punctum plug
Placebo Comparator: Placebo Vehicle Punctum Plug
Placebo punctum plug insertion
Drug: Placebo Vehicle Punctum Plug
Hydrogel punctum plug without dexamethasone


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has provided written informed consent, approved by the appropriate institutional review board; and is able to comply with study requirements and visit schedule
  • Is greater than or equal to 21 years of age
  • Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber intraocular lens

Exclusion Criteria:

  • Any intraocular inflammation in the study eye present during the screening slit lamp examination
  • Score greater than "0" on the Ocular Pain Assessment at Screening
  • Compromised immune system or an autoimmune disease that in the opinion of the Investigator could affect the quality of the ocular surface
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01666210

United States, Illinois
Chicago Cornea Consultants, Ltd.
Hoffman Estates, Illinois, United States, 60169
Sponsors and Collaborators
Ocular Therapeutix, Inc.
  More Information

Responsible Party: Ocular Therapeutix, Inc. Identifier: NCT01666210     History of Changes
Other Study ID Numbers: OTX-12-002
Study First Received: August 14, 2012
Results First Received: February 9, 2016
Last Updated: March 15, 2017

Additional relevant MeSH terms:
Capsule Opacification
Pathologic Processes
Lens Diseases
Eye Diseases
Dexamethasone acetate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 16, 2017